Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics (NASDAQ: SYRE) granted equity inducement awards to six non-executive employees under its 2018 Equity Inducement Plan.

Rhea-AI Summary

Spyre Therapeutics (NASDAQ: SYRE) granted equity inducement awards to six non-executive employees under its 2018 Equity Inducement Plan.

The awards include stock options for 58,843 shares at an exercise price of $88.89 with a 10-year term, plus 2,134 RSUs, all subject to multi-year vesting and continued service.

Positive

• Equity inducement of 58,843 options and 2,134 RSUs to attract talent
• 10-year option term at $88.89 aligns employees with long-term share performance
• Structured multi-year vesting supports employee retention and continuity

Negative

• New equity awards may modestly dilute existing shareholders over time
• Additional stock-based compensation will add to future compensation expense

Argus Jul 6 session 7 alerts

+2.44% close to close 0.8x rel. volume Open Argus

Details

News Market Reaction – SYRE

$7.52B Mkt Cap at Peak Alert

On Jul 6, the first trading day after this news, SYRE closed 2.44% above the previous close. Our momentum scanner recorded 7 alerts for this stock that day.

Data tracked by StockTitan Argus for the Jul 6 session.

Key Figures

Stock options granted: 58,843 shares RSUs granted: 2,134 RSUs Employees receiving awards: 6 employees +5 more

Stock options granted

58,843 shares

Aggregate options to six non-executive employees under 2018 Plan

RSUs granted

2,134 RSUs

Equity inducement awards to six non-executive employees

Employees receiving awards

6 employees

Non-executive hires receiving inducement equity grants

Option term

10-year term

Duration of granted stock options

Exercise price

$88.89

Exercise price set at July 1, 2026 Nasdaq closing price

Initial vesting tranche

1/4th of shares

Options vest 25% on first anniversary of employee start date

Ongoing option vesting

1/48th monthly

Remaining option shares vest monthly thereafter

RSU vesting schedule

1/4th annually

RSUs vest in four annual installments tied to quarterly dates

Historical Context

5 past events · Latest: Jun 15

5 events

1. Jun 15

   Phase 2 trial data

   24h Move

   +3.5%

   Positive SPY002 SKYLINE Part A ulcerative colitis data with key endpoints met.

2. Jun 05

   Inducement awards

   24h Move

   -2.9%

   Stock option inducement grants to four non-executive employees under 2018 plan.

3. Jun 03

   Trial enrollment update

   24h Move

   +6.3%

   Completion of enrollment in SKYWAY Phase 2 basket trial for SPY072.

4. May 26

   Conference participation

   24h Move

   -1.6%

   Announcement of participation in two June 2026 healthcare investor conferences.

5. May 05

   1Q26 earnings report

   24h Move

   +2.7%

   Q1 2026 results with strong cash position and multiple Phase 2 readouts planned.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, equity inducement awards, nasdaq listing rule 5635(c)(4), exercise price

4 terms

restricted stock units financial

"and 2,134 restricted stock units (“RSUs”) to six non-executive employees"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

equity inducement awards financial

"as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity"

Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.

nasdaq listing rule 5635(c)(4) regulatory

"with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"a 10-year term and an exercise price equal to $88.89, the closing price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 58,843 shares of common stock of Spyre and 2,134 restricted stock units (“RSUs”) to six non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options and RSUs were approved on July 1, 2026 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options were granted with a 10-year term and an exercise price equal to $88.89, the closing price per share of Spyre's common stock as reported by Nasdaq on July 1, 2026. The options granted to the employees shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Spyre through the applicable vesting dates. The RSUs granted to the employees shall vest as to one-fourth (1/4^th) of the shares subject to the respective RSUs on each anniversary of the next February 15, May 15, August 15, or November 15 occurring on or after the employee’s start date, subject to continuous service with Spyre through the applicable vesting dates. The stock options and RSUs are subject to the terms of the 2018 Plan.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

For more information, please visit http://spyre.com.

For Investors:
Eric McIntyre
SVP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement equity awards did Spyre Therapeutics (NASDAQ: SYRE) grant in July 2026?

Spyre Therapeutics granted stock options for 58,843 shares and 2,134 restricted stock units as inducement awards to six non-executive employees. According to Spyre, these awards were granted under its 2018 Equity Inducement Plan and were material to each employee’s acceptance of employment.

What is the exercise price and term of Spyre Therapeutics (SYRE) inducement stock options?

The inducement stock options have a 10-year term and an exercise price of $88.89 per share. According to Spyre, this price equals the July 1, 2026 Nasdaq closing price of its common stock, aligning option value with the market at grant.

How do Spyre Therapeutics (SYRE) inducement stock options vest for new employees?

Spyre’s inducement stock options vest 25% on the first anniversary of each employee’s start date, with the remaining shares vesting monthly thereafter. According to Spyre, one-forty-eighth of the option shares vests each month, subject to continuous service through the applicable vesting dates.

What is the vesting schedule for Spyre Therapeutics (SYRE) inducement RSUs?

Spyre’s inducement RSUs vest in four equal annual installments tied to quarterly dates. According to Spyre, 25% of each RSU grant vests on each anniversary of the next February 15, May 15, August 15, or November 15 after the employee’s start date, subject to continuous service.

Why did Spyre Therapeutics grant inducement awards under the 2018 Equity Inducement Plan?

Spyre used its 2018 Equity Inducement Plan to grant stock options and RSUs that were material to each employee’s job acceptance. According to Spyre, these awards were approved by the independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4) for new hires.

How many employees received Spyre Therapeutics (SYRE) inducement equity grants in July 2026?

Six non-executive employees received inducement equity grants consisting of stock options and RSUs. According to Spyre, the Compensation Committee approved these awards on July 1, 2026 as part of employment offers, using shares available under the 2018 Equity Inducement Plan.